fda and glp-1 Approves First Generic Liraglutide for Weight Loss FDA Moves to Restrict Mass-Marketed

Fewer studies have been carried out with DPP-4 inhibitors

Like blood pressure or diabetes medications, GLP-1s address an ongoing physiological issue and are a lifelong medication for many

These are the ones well focus on here

Comparing Semaglutide and Tirzepatide While both semaglutide and tirzepatide are effective in managing obesity and type 2 diabetes, their mechanisms of action differ slightly: Semaglutide is a GLP-1 receptor agonist that primarily works by: - Slowing gastric emptying - Reducing appetite through brain signaling - Stimulating insulin release from the pancreas - Decreasing glucagon secretion Tirzepatide, on the other hand, is a dual GIP and GLP-1 receptor agonist, often referred to as a "twincretin"[8]

People who start out at a higher BMI typically see faster results and greater percentage of weight loss than others

Meng F, Wang J, Wang L, Zou W (2025) Glucose metabolism impairment in major depressive disorder